查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1840716

犬异位性皮肤炎市场（依治疗类型、产品类型、通路和形式类型）－2025-2032 年全球预测

Canine Atopic Dermatitis Market by Treatment Type, Product Type, Distribution Channel, Form Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，犬异位性皮肤炎市场将成长 33 亿美元，复合年增长率为 8.67%。

主要市场统计数据
基准年2024年 16.9亿美元
预计2025年 18.4亿美元
预测年份：2032年 33亿美元
复合年增长率（%） 8.67%

我们为相关人员准备了一份简洁的介绍，概述了犬异位性皮肤炎的临床复杂性、未满足的需求和策略紧迫性。

犬异位性皮肤炎是免疫学、慢性病管理和不断发展的治疗方案的复杂交叉领域，需要製造商、临床医生和经销商进行仔细的战略考虑。异位性皮肤炎的多因子特性导致治疗方法迅速多样化，包括生物目标、全身性抗发炎药物、补充营养保健品和缓解症状的外用药物。随着相关人员重新评估其优先事项，临床疗效、安全性和犬主偏好已成为影响其商业化和临床应用的关键因素。

同时，兽药治疗的监管和报销环境也变得更加微妙，对临床证据和上市后安全监测的审查也更加严格。这种转变使得严谨的研究设计、真实世界证据收集和主动药物安全检测的重要性日益凸显。因此，企业必须比以往更加紧密地协调临床开发、生产品质和市场投放计划。本执行摘要的其余部分总结了最重要的趋势，提供了细分市场和区域考量，分析了2025年美国关税的影响，并为寻求可持续竞争优势的市场参与企业提出了优先且可行的建议。

治疗创新、监管压力和饲主期望的变革正在推动犬皮肤病治疗途径的重新定义

受科技进步、饲主期望变化以及整个供应链营运压力的推动，犬异位性皮肤炎的治疗方法正在经历重大变革。分子生物学和免疫学领域的突破，使生物製药（尤其是单株抗体）从实验性疗法提升为切实可行的治疗方法，能够提供针对性的缓解，并具有良好的安全性。同时，犬主越来越多地寻求将处方疗法与营养补充剂和差异化局部护理相结合的综合护理途径，这为横跨临床和健康类别的混合产品策略创造了空间。

不断变化的法规和付款人行为也在改变商业性模式。监管机构强调，对于仿单标示外人体应用，需要强有力的证据包和清晰的标籤，并鼓励申办方儘早投资于对照试验和长期安全监测。在商业方面，全通路分销和远端医疗正在重塑医疗管道，使专科诊所和线上零售商能够与传统兽医诊所共存。技术支援的依从性工具和数位化互动策略正在提高饲主的依从性，并提供更丰富的真实世界资料集，以支援产品差异化。这些转变正在加速产品生命週期决策，提升策略伙伴关係关係的重要性，并需要能够回应临床和市场主导需求的敏捷营运模式。

评估 2025 年美国宣布的关税对兽医皮肤病药物投入和定价的累积营运和供应链影响

美国宣布的2025年关税，为采购用于皮肤病治疗的原料、成品和特殊零件的公司带来了重要的考量。在整个价值链中，进口关税和相关的管理成本增加了某些活性原料药、辅料和包装材料的到岸成本。这促使许多公司重新审视库存策略，增加关键原材料的安全库存，并重新评估前置作业时间，以降低与关税相关的波动风险。

采购团队已采取应对措施，加快供应商多元化步伐，优先考虑近岸外包和区域供应商，以缩短物流路线并减少对关税的依赖。虽然这些措施提高了韧性，但也引发了供应品质、监管合规性和成本竞争力方面的问题。由于製造商需要在需求下降的风险与将部分成本转嫁给兽医诊所和零售通路之间取得平衡，定价策略面临压力。与此同时，谈判能力有限的小型创新企业正在寻求合约製造外包伙伴关係和批量采购协议，以保护利润率。

临床开发项目正遭受二次影响。专用试剂和国际CRO服务成本的上涨，正在推动方案效率和选择性入组策略的提升。监管提交现在需要额外的文件来证明供应链管理以及供应商变更后产品的一致性。总体而言，2025年的关税格局强化了动态采购、积极主动的相关人员沟通以及基于情景的财务规划的必要性，以保障供应的连续性并保持最终用户的可负担性。

细分主导的情报揭示了治疗类型、产品形式、分销管道和处方途径如何影响商业化策略

细緻的细分框架揭示了临床和商业层面的机会与限制。从治疗类型来看，市场涵盖生物製药（以膳食补充剂配方为代表）、透过注射或口服片剂进行的全身性治疗以及以乳膏、凝胶、洗髮精和喷雾剂等形式提供的外用药物。治疗类型的多样性要求每个治疗类别都有独特的监管途径、发展时间表和临床医生教育策略。

产品类型细分透过区分非处方笺药和处方药，进一步区分了市场方法，每种途径都会影响行销合规性、经销伙伴和照护现场对话。分销管道细分揭示了关键的上市选择，包括线上零售商、专业宠物商店、传统药局以及兽医诊所和诊所，每种选择都提供不同的利润概况、通路控制和资料收集机会。最后，剂型考量——从乳膏和凝胶到注射剂、口服片剂、洗髮精和喷雾剂——会影响配方复杂性、稳定性要求和饲主依从性动态。这些相互关联的细分轴要求製造商将其临床证据生成、包装和商业化计划与治疗类型、监管环境、渠道策略和产品形式的特定交集相结合，以最大限度地提高采用率和长期治疗成功率。

亚太地区、欧洲、中东和非洲的区域动态和跨境考虑重塑了犬类药物的​​取得和报销

区域动态对治疗药物的可及性、定价和上市速度有着决定性的影响。在美洲，成熟的兽医网络和不断增长的宠物医疗保健支出推动了对差异化疗法的强劲需求，同时监管部门也更倾向于循证核准和明确的安全性。在该地区运营的製造商通常优先考虑与专科诊所建立合作伙伴关係并采用整合的分销模式，以确保临床医生的认可并支持产品上市后的监测活动。

欧洲、中东和非洲地区（EMEA）的监管和报销环境差异较大，各国的兽医法规和进口规则各不相同，需要弹性的打入市场策略。符合当地监管标准的临床数据和谨慎的跨境物流至关重要。製造商可以从区域经销伙伴和本地製造中受益，以应对海关和合规挑战。

在亚太地区，宠物拥有量的快速成长和兽医服务的扩张为加速推广创造了机会，尤其是在都市区对高端疗法的认知度和投资更高。然而，市场准入必须考虑多样化的法律规范、某些生技药品不断变化的低温运输，以及营养补充剂和外用药的独特区域偏好。在任何地区，将临床讯息与当地兽医执业模式和饲主的期望相结合，并根据当地限制调整供应链和定价策略，将决定商业性成功。

定义犬异位性皮肤炎治疗生态系中成功参与者的关键企业行为、竞争差异化和合作模式

成功的公司凭藉专注的研发投入、灵活的生产策略和差异化的商业化模式脱颖而出。主要企业正在投入资源开发靶向生物製药平台，推进安全性和有效性得到验证的单株抗体候选药物，同时开发营养补充剂系列，以提高患者用药依从性并拓宽可及疗法的范围。这些整合的产品组合支援分级交付，以满足临床需求和所有者的偏好。

策略伙伴关係十分常见，企业与临床研究机构、契约製造、分销专家及其他各方携手合作，以加速研发进度并确保产能。重视全通路分销（包括数位优先互动工具和远距远端医疗诊断支援）的企业正在改善业主教育和依从性追踪。此外，创新者正在投资上市后证据收集，以证实长期安全声明并支持产品标籤扩展。优化供应链冗余、建立区域製造节点并维护透明品质系统的企业正在缩短供货时间并增强与兽医专业人士的信任。最终，企业的成功取决于将科学差异化与切合实际的商业执行和弹性运作相结合。

为产业领导者提供优先的战术性和策略槓桿的可行建议，以加速采用、优化供应链并加强市场进入

产业领导者应采取多管齐下的策略，在短期商业利益与中期平台建设之间取得平衡。首先，优先为差异化治疗方法获取临床证据，重点关注对临床医生和药物持有者至关重要的终点，例如持久缓解瘙痒、现实世界安全性以及改善生活品质指标。投资于务实的临床试验和严格的核准后监测，将增强临床医师的信心，并为产品说明书的完善提供机会。

其次，实现采购多元化，并调整供应链架构，以缓解关税和物流波动。与区域供应商建立关係，认证多家製造外包，并透过与分销伙伴更紧密的合作来改善需求预测，可以降低关税带来的成本衝击。第三，推行全通路市场推广模式，将兽医教育、饲主的数位互动以及与精选零售商的合作结合。依照产品的监管状态客製化通讯。非处方药的宣传应强调安全、常规使用，处方药宣传活动应以临床有效性和兽医指导为中心。

第四，利用策略联盟，充分利用互补能力，例如检测方法开发、依从性技术和在地化监管支援。最后，将定价策略与已证实的价值相结合，同时准备战术性返利，并与大型兽医网络进行战术性的合约试点。这些行动要充分考虑竞争格局，才能巩固您的市场准入之路，提高您应对宏观环境波动的韧性，并在竞争格局中打造可持续的差异化优势。

透明的调查方法详细说明了混合方法、资料检验过程以及构成分析和建议基础的限制。

本执行摘要的分析采用了混合方法，结合了初步定性访谈、结构化二次研究以及跨多个资料流的三角检验，以确保获得可靠且可操作的见解。主要输入包括对全科和皮肤科专科诊所的执业兽医、製造和分销机构的采购和运营负责人以及治疗创新公司的业务发展主管的深入访谈。这些访谈提供了关于临床优先事项、供应链漏洞和通路经济效益的第一线观点。

二次研究包括同行评审的犬皮肤病病理学和治疗效果文献、监管指南文件、公开的公司文件以及临床试验註册。本研究对不同资讯来源的数据进行了交叉检验，以确定一致的主题并协调不同的发现。透过情境建模，进一步增强了方法的严谨性，以检验营运和定价结果对关税相关中断和供应链延迟的敏感度。在存在不确定性的情况下，分析强调风险调整后的建议和假设的透明度，以支持明智的决策。

总结性结论提炼了策略要点、风险考量以及相关人员在犬皮肤病学不断发展的领域中应采取的后续步骤。

犬异位性皮肤炎的不断发展既带来了策略挑战，也带来了实际的机会。标靶治疗的进步和依证的日益成熟，为临床差异化开闢了新的途径，而饲主行为和分销模式的转变也拓展了市场管道。同时，关税和供应链复杂性等宏观动态要求我们保持营运警觉并制定灵活的策略规划。

整合严谨的临床开发、弹性的供应链设计和全通路商业化的相关人员最有可能获得新的价值。关键挑战包括：取得临床相关证据、投资多元化采购和生产，以及根据已证实的治疗价值调整定价和存取策略。透过优先考虑这些领域并遵循切实可行的建议，企业能够克服当前的困境，为犬皮肤病学领域的成长和治疗领导地位奠定持久的基础。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 越来越多地采用生物目标疗法进行治疗
  • 扩展兽医远端皮肤病学平台，用于远端监测异位性皮肤病
  • 增加基于微生物组的局部治疗以恢復犬的皮肤屏障功能
  • 个人化营养补充品的成长旨在支持过敏犬的免疫反应
  • 开发植物来源的植物化学配方，用于天然缓解狗的过敏
  • 整合穿戴式感测器技术即时追踪狗的皮肤炎发展
  • 以订阅为基础的预防保健套餐的出现，重点关注狗狗的长期皮肤健康
  • 新型疗法的监管核准趋势和不断变化的专利格局

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 犬异位性皮肤炎市场（依治疗类型）

  • 生物製药
    • 单株抗体
  • 营养补充品
    • 补充
  • 全身性治疗
    • 注射
    • 口服锭剂
  • 外用药物
    • 乳霜和凝胶
    • 洗髮精
    • 喷

9. 犬异位性皮肤炎市场（依产品类型）

  • 非处方药
  • 处方笺

第 10 章犬异位性皮肤炎市场（依分销管道）

  • 网路零售
  • 宠物专卖店
  • 药局
  • 兽医诊所

第 11 章犬异位性皮肤炎市场（依形式类型）

  • 乳霜和凝胶
  • 注射
  • 口服锭剂
  • 洗髮精
  • 喷

第12章犬异位性皮肤炎市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章犬异位性皮肤炎市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 犬异位性皮肤炎市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Zoetis Inc.
    • Elanco Animal Health Incorporated
    • Boehringer Ingelheim International GmbH
    • Merck Sharp & Dohme Corp.
    • Hill's Pet Nutrition, Inc.
    • Virbac SA
    • Ceva Sante Animale SA
    • Dechra Pharmaceuticals plc
    • Vetoquinol SA
    • Royal Canin SAS
Product Code: MRR-A339DAEFA20E

The Canine Atopic Dermatitis Market is projected to grow by USD 3.30 billion at a CAGR of 8.67% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.69 billion
Estimated Year [2025] USD 1.84 billion
Forecast Year [2032] USD 3.30 billion
CAGR (%) 8.67%

A concise introduction outlining the clinical complexity, unmet needs, and strategic urgency shaping the canine atopic dermatitis landscape for stakeholders

Canine atopic dermatitis presents a complex intersection of immunology, chronic care management, and evolving treatment options that demand careful strategic consideration from manufacturers, clinicians, and distributors. The condition's multifactorial nature has driven rapid diversification of therapeutic approaches, spanning targeted biological agents, systemic anti-inflammatory regimens, adjunctive nutraceuticals, and symptom-relief topical formulations. As stakeholders reassess priorities, clinical efficacy, safety profiles, and owner preferences are emerging as the dominant axes shaping commercialization and clinical adoption.

In parallel, the regulatory and reimbursement environment for veterinary therapeutics is becoming more nuanced, with increased scrutiny on clinical evidence and post-market safety monitoring. This shift amplifies the importance of rigorous trial design, real-world evidence collection, and proactive pharmacovigilance. Consequently, companies must coordinate clinical development, manufacturing quality, and go-to-market planning more tightly than in prior cycles. The remainder of this executive summary synthesizes the most consequential trends, presents segmentation and regional insights, examines 2025 tariff implications in the United States, and concludes with prioritized, actionable recommendations for market participants seeking sustained competitive advantage.

Transformative shifts in therapeutic innovation, regulatory pressures, and pet owner expectations driving a redefinition of treatment pathways in canine dermatology

The therapeutic landscape for canine atopic dermatitis is undergoing transformative change driven by scientific advances, shifting pet owner expectations, and operational pressures across supply chains. Breakthroughs in molecular biology and immunology have elevated biologics, particularly monoclonal antibodies, from experimental options to practical therapies that deliver targeted relief with favorable safety profiles. Simultaneously, owners increasingly demand integrated care pathways that combine prescription therapies with nutraceutical support and differentiated topical care, creating space for hybrid product strategies that straddle clinical and wellness categories.

Regulatory evolution and payer behavior are also altering commercial calculus. Regulators are emphasizing robust evidence packages and clearer labeling on off-label human drug adaptations, prompting sponsors to invest earlier in controlled studies and long-term safety monitoring. On the commercial front, omnichannel distribution and telemedicine are reshaping access, allowing specialty clinics and online retailers to coexist with traditional veterinary practices. Technology-enabled adherence tools and digital engagement strategies are enhancing owner compliance and enabling richer real-world datasets to support product differentiation. Together, these shifts are accelerating product lifecycle decisions, elevating the importance of strategic partnerships, and requiring nimble operating models that can respond to both clinical and market-driven imperatives.

Assessing the cumulative operational and supply chain effects of United States tariff measures announced in 2025 on veterinary dermatology inputs and pricing dynamics

Tariff measures announced in the United States in 2025 have introduced a material set of considerations for companies sourcing raw materials, finished goods, and specialized components for dermatologic therapies. Across the value chain, import duties and related administrative costs have increased landed costs for certain active pharmaceutical ingredients, excipients, and packaging supplies. This has led to a recalibration of inventory strategies, with many firms extending safety stocks for critical inputs and re-evaluating lead times to mitigate exposure to customs-related variability.

Procurement teams have responded by accelerating supplier diversification efforts, prioritizing nearshoring and regional suppliers to shorten logistical pathways and reduce tariff dependency. While these efforts can enhance resilience, they also raise questions about supply quality, regulatory alignment, and cost competitiveness. Pricing strategies have faced pressure, as manufacturers weigh partial cost pass-through to veterinary clinics and retail channels against the risk of dampening demand. In parallel, smaller innovators with limited negotiating leverage have explored contract manufacturing partnerships and bundled sourcing agreements to preserve margins.

Clinical development programs have felt secondary effects; increased costs for specialized reagents and international CRO services have prompted tighter protocol efficiency and selective enrollment strategies. Regulatory dossiers have required additional documentation to demonstrate supply chain controls and product consistency when supplier changes occur. Overall, the 2025 tariff landscape has reinforced the need for dynamic sourcing, proactive stakeholder communication, and scenario-based financial planning to protect continuity of supply and maintain affordability for end users.

Segment-driven intelligence revealing how treatment types, product forms, distribution channels, and prescription pathways converge to inform commercialization strategies

A nuanced segmentation framework illuminates opportunities and constraints across both clinical and commercial dimensions. When viewed through the lens of treatment type, the market spans biologics-where monoclonal antibodies represent a focal innovation vector-nutraceuticals typified by supplemental formulations, systemic therapies delivered via injections and oral tablets, and topicals available as creams and gels, shampoos, and sprays. This treatment-type diversity mandates distinct regulatory pathways, development timelines, and clinician education strategies for each therapeutic category.

Product-type segmentation further differentiates market approaches by delineating OTC options from prescription-only therapies, with each pathway shaping marketing compliance, distribution partnerships, and point-of-care conversations. Distribution channel segmentation highlights critical go-to-market choices across online retail, pet specialty stores, traditional pharmacies, and veterinary hospitals and clinics, each offering different margin profiles, channel controls, and data capture opportunities. Finally, form-type considerations-ranging from creams and gels to injections, oral tablets, shampoos, and sprays-affect formulation complexity, stability requirements, and owner adherence dynamics. Taken together, these interlocking segmentation axes demand that manufacturers tailor clinical evidence generation, packaging, and commercialization plans to the specific intersection of treatment type, regulatory status, channel strategy, and product form to maximize adoption and long-term therapeutic success.

Regional dynamics and cross-border considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that are reshaping access and reimbursement for canine therapies

Regional dynamics exert a decisive influence on access, pricing, and the speed of therapeutic adoption. In the Americas, well-established veterinary care networks and growing pet healthcare spend are driving strong demand for differentiated therapies, while regulatory expectations favor evidence-based approvals and clear safety profiles. Manufacturers operating in this region often prioritize partnerships with specialty clinics and integrated distribution models to ensure clinician buy-in and to support post-launch surveillance initiatives.

The Europe, Middle East & Africa region presents a heterogeneous regulatory and reimbursement environment where country-level variations in veterinary regulation and import rules require flexible market entry strategies. Here, clinical data that aligns with local regulatory standards and careful navigation of cross-border logistics are essential. Manufacturers can benefit from regional distribution partnerships and localized manufacturing arrangements to address tariff and compliance challenges.

Across Asia-Pacific, rapid pet ownership growth and expanding veterinary services are creating opportunities for accelerated uptake, particularly in urban centers where awareness and willingness to invest in premium therapies are higher. However, market entry must consider diverse regulatory frameworks, variable cold-chain infrastructure for certain biologics, and localized preferences for nutraceutical and topical solutions. In all regions, aligning clinical messaging to local veterinary practice patterns and owner expectations, while adapting supply chain and pricing strategies to regional constraints, will determine commercial success.

Key corporate behaviors, competitive differentiation, and collaboration models that define successful players in the canine atopic dermatitis therapeutic ecosystem

Successful firms are distinguishing themselves through a combination of focused R&D investment, flexible manufacturing strategies, and differentiated commercialization models. Leading companies are channeling resources into targeted biologic platforms, advancing monoclonal antibody candidates with clear safety and efficacy narratives, while simultaneously developing supportive nutraceutical lines that enhance adherence and broaden total addressable therapy bundles. These integrated portfolios enable a tiered offering that meets both clinical needs and owner preferences.

Strategic partnerships are common, with firms forming alliances across clinical research organizations, contract manufacturers, and distribution specialists to compress development timelines and secure capacity. Companies prioritizing omnichannel distribution, including digital-first engagement tools and telehealth-enabled diagnostic support, are improving owner education and adherence tracking. Additionally, innovators are investing in post-market evidence collection to substantiate long-term safety claims and to support label expansions. Operational excellence is also emerging as a competitive advantage: those that optimize supply chain redundancy, establish regional manufacturing nodes, and maintain transparent quality systems reduce time-to-supply disruptions and reinforce trust with veterinary professionals. Ultimately, corporate success hinges on aligning scientific differentiation with pragmatic commercialization execution and resilient operations.

Actionable recommendations offering prioritized tactical and strategic moves for industry leaders to accelerate adoption, optimize supply chains, and strengthen market access

Industry leaders should adopt a multi-pronged strategy that balances near-term commercialization wins with medium-term platform building. First, prioritize clinical evidence generation for differentiated therapies, focusing on endpoints that matter to clinicians and owners such as sustained pruritus reduction, safety in real-world settings, and improvement in quality-of-life metrics. Investing in pragmatic trials and robust post-approval surveillance will accelerate clinician confidence and support label-strengthening opportunities.

Second, diversify sourcing and adapt supply chain architecture to mitigate tariff and logistics volatility. Establishing regional supplier relationships, qualifying multiple contract manufacturers, and improving demand forecasting through closer collaboration with distribution partners will reduce vulnerability to tariff-induced cost shocks. Third, pursue omnichannel go-to-market models that combine veterinary clinic education, digital engagement for owners, and selective retail partnerships. Tailor messaging to the product's regulatory status-OTC communications should emphasize safe, everyday use while prescription campaigns must center on clinical efficacy and veterinarian guidance.

Fourth, leverage strategic alliances to access complementary capabilities, including assay development, adherence technologies, and localized regulatory support. Finally, align pricing strategies with demonstrated value while preparing tactical rebates or value-based contracting pilots with large veterinary networks. Collectively, these actions will strengthen market access pathways, improve resilience against macro disruptions, and create durable differentiation in a competitive landscape.

Transparent research methodology detailing the mixed-methods approach, data validation processes, and limitations underpinning the analysis and recommendations

The analysis underpinning this executive summary employed a mixed-methods approach combining primary qualitative interviews, structured secondary research, and triangulation across multiple data streams to ensure robust, actionable insights. Primary inputs included in-depth interviews with practicing veterinarians across general practice and dermatology specialty clinics, procurement and operations leaders within manufacturing and distribution organizations, and business development executives from therapeutic innovators. These interviews provided first-line perspectives on clinical priorities, supply chain vulnerabilities, and channel economics.

Secondary research encompassed peer-reviewed literature on canine dermatologic pathophysiology and treatment efficacy, regulatory guidance documents, and publicly available corporate filings and clinical trial registries. Data points from different sources were cross-validated to identify consistent themes and to reconcile divergent findings. Methodological rigor was further enhanced by scenario modeling to test the sensitivity of operational and pricing outcomes to tariff-related disruptions and supply chain delays. Limitations include the inherent variability in regional regulatory regimes and the evolving evidence base for newer therapeutic classes; where uncertainties existed, the analysis emphasized risk-adjusted recommendations and transparency about assumptions to support informed decision-making.

Concluding synthesis that distills strategic imperatives, risk considerations, and next steps for stakeholders navigating the evolving canine dermatology landscape

The evolving canine atopic dermatitis environment presents both strategic challenges and tangible opportunities. Advances in targeted therapies and a maturing evidence base are creating new pathways for clinical differentiation, while shifts in owner behavior and distribution models are expanding routes to market. At the same time, macro-level dynamics such as tariff actions and supply chain complexity necessitate heightened operational vigilance and flexible strategic planning.

Stakeholders that integrate rigorous clinical development with resilient supply chain design and omnichannel commercialization will be best positioned to capture emerging value. Key imperatives include generating clinically relevant evidence, investing in diversified sourcing and manufacturing, and aligning pricing and access strategies with demonstrated therapeutic value. By prioritizing these areas and following the actionable recommendations outlined, organizations can navigate current headwinds and establish a durable foundation for growth and therapeutic leadership in canine dermatology.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of targeted biologic therapies for canine atopic dermatitis management
  • 5.2. Expansion of veterinary teledermatology platforms for remote atopic skin condition monitoring
  • 5.3. Increasing availability of microbiome-based topical treatments to restore canine skin barrier function
  • 5.4. Growth of personalized nutritional supplements designed to support immune responses in atopic dogs
  • 5.5. Development of plant-derived phytochemical formulations for natural canine allergy relief
  • 5.6. Integration of wearable sensor technology for real-time tracking of canine dermatitis flare ups
  • 5.7. Emergence of subscription-based preventative care packages focused on long-term skin health in dogs
  • 5.8. Regulatory approval trends and patent landscape evolution for novel canine atopic dermatitis therapeutics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Canine Atopic Dermatitis Market, by Treatment Type

  • 8.1. Biologics
    • 8.1.1. Monoclonal Antibodies
  • 8.2. Nutraceuticals
    • 8.2.1. Supplements
  • 8.3. Systemic Therapies
    • 8.3.1. Injections
    • 8.3.2. Oral Tablets
  • 8.4. Topicals
    • 8.4.1. Creams & Gels
    • 8.4.2. Shampoo
    • 8.4.3. Sprays

9. Canine Atopic Dermatitis Market, by Product Type

  • 9.1. Otc
  • 9.2. Prescription

10. Canine Atopic Dermatitis Market, by Distribution Channel

  • 10.1. Online Retail
  • 10.2. Pet Specialty Stores
  • 10.3. Pharmacies
  • 10.4. Veterinary Hospitals Clinics

11. Canine Atopic Dermatitis Market, by Form Type

  • 11.1. Creams & Gels
  • 11.2. Injections
  • 11.3. Oral Tablets
  • 11.4. Shampoo
  • 11.5. Sprays

12. Canine Atopic Dermatitis Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Canine Atopic Dermatitis Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Canine Atopic Dermatitis Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Zoetis Inc.
    • 15.3.2. Elanco Animal Health Incorporated
    • 15.3.3. Boehringer Ingelheim International GmbH
    • 15.3.4. Merck Sharp & Dohme Corp.
    • 15.3.5. Hill's Pet Nutrition, Inc.
    • 15.3.6. Virbac S.A.
    • 15.3.7. Ceva Sante Animale S.A.
    • 15.3.8. Dechra Pharmaceuticals plc
    • 15.3.9. Vetoquinol S.A.
    • 15.3.10. Royal Canin S.A.S.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. CANINE ATOPIC DERMATITIS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. CANINE ATOPIC DERMATITIS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CANINE ATOPIC DERMATITIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY INJECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY INJECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY INJECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY INJECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY INJECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY INJECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ORAL TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ORAL TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ORAL TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ORAL TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ORAL TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ORAL TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY CREAMS & GELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY CREAMS & GELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY CREAMS & GELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY CREAMS & GELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY CREAMS & GELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY CREAMS & GELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SHAMPOO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SHAMPOO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SHAMPOO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SHAMPOO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SHAMPOO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SHAMPOO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SPRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SPRAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SPRAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SPRAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SPRAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SPRAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY OTC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY OTC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY OTC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY OTC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY OTC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY OTC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PET SPECIALTY STORES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PET SPECIALTY STORES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PET SPECIALTY STORES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PET SPECIALTY STORES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PET SPECIALTY STORES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PET SPECIALTY STORES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY VETERINARY HOSPITALS CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY VETERINARY HOSPITALS CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY VETERINARY HOSPITALS CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY VETERINARY HOSPITALS CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY VETERINARY HOSPITALS CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY VETERINARY HOSPITALS CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY CREAMS & GELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY CREAMS & GELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY CREAMS & GELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY CREAMS & GELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY CREAMS & GELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY CREAMS & GELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY INJECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY INJECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY INJECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY INJECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY INJECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY INJECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ORAL TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ORAL TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ORAL TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ORAL TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ORAL TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY ORAL TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SHAMPOO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SHAMPOO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SHAMPOO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SHAMPOO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SHAMPOO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SHAMPOO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SPRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SPRAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SPRAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SPRAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SPRAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY SPRAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. MIDDLE EAST CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 271. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 272. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 273. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
  • TABLE 274. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
  • TABLE 275. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 278. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 279. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY FORM TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL CANINE ATOPIC DERMATITIS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 306. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 307. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 308. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY NUTRACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 309. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 310. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY SYSTEMIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 311. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
  • TABLE 312. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
  • TABLE 313. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 316. ASEAN CANINE ATOPIC DERMATITIS MARKET SIZE, BY D